In a phase II, randomized, placebo-controlled, double-blind cross-over trial, Jama et al. show that delivery of short-chain fatty acids via acetylated and butyrylated high-amylose maize starch (HAMSAB) supplementation result in a clinically relevant reduction in 24-hour systolic blood pressure in patients with essential hypertension.
- Hamdi A. Jama
- Dakota Rhys-Jones
- Francine Z. Marques
